Toboroz
Ketamine maintenance treatment for depression: A multicenter open-label randomized controlled trial (PreKET)
2025-521330-29-00· 2. fázis· Ostfold Hospital Trust· Forrás
Toboroz
A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-escalation strategies in patients who respond to treatment.
NCT01491815· 4. fázis· Karolinska Institutet· Forrás
Toboroz
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
2025-525009-18-00· 3. fázis· Incyte Corp.· Forrás
Toboroz
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
NCT07476729· 3. fázis· Charite University, Berlin, Germany· Forrás
Toboroz
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· 3. fázis· AstraZeneca· Forrás
Még nem toboroz
A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)
2025-524439-38-00· 2. fázis· Oslo Universitetssykehus HF· Forrás
Még nem toboroz
Reassessment of statin-associated muscle symptoms in adults with familial hypercholesterolemia
2025-521589-83-00· 4. fázis· Oslo University Hospital HF· Forrás
Toboroz
Implementing the 6th Generation Cardiac Troponin T
NCT07936630· Rasmus Bo Hasselbalch· Forrás
Contact: Kristin Aakre, Md, PhD
Toboroz
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654· 3. fázis· Boehringer Ingelheim· Forrás
Még nem toboroz
Does a higher radiation dose prolong survival of patients with limited-stage small cell lung cancer receiving immunotherapy after chemotherapy and radiation therapy (DAHRTS trial)?
2026-525513-31-00· 3. fázis· Norges Teknisk-Naturvitenskapelige Universitet NTNU· Forrás
Toboroz
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Aminoglycosides in Early Sepsis
NCT06712641· 4. fázis· University Hospital, Akershus· Forrás
Toboroz
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445· 3. fázis· Revolution Medicines, Inc.· Forrás
Toboroz
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
NCT07223814· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
A Phase 2, Randomized, Double-Blind, Double-Dummy Study Evaluating the Efficacy, Safety and Biomarkers Effect of ILB® versus Riluzole in participants with Amyotrophic Lateral Sclerosis
2024-513927-18-00· 2. fázis· Oslo University Hospital HF· Forrás
Toboroz
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
NCT07222332· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
NCT06980480· 3. fázis· Takeda· Forrás
Toboroz
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
NCT06932562· 3. fázis· European Myeloma Network B.V.· Forrás
Toboroz
Modern Technologies in Lower Respiratory Tract Infections in Children
NCT07381790· Helse Møre og Romsdal HF· Forrás
Contact: Kari Risnes, Professor
Toboroz
Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia
2025-520982-39-00· 3. fázis· Universita Degli Studi Di Milano Bicocca· Forrás
Még nem toboroz
The ALPINE trial: a phase 1-2 study of intra-arterial [177Lu]Lu-PSMA-I&T for progressive or recurrent intracranial adult type diffuse glioma
2023-504696-24-00· 1/2. fázis· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Forrás
Toboroz
PIRTOBRUTINIB AND GLOFITAMAB IN MANTLE CELL LYMPHOMA
2024-512922-27-00· 2. fázis· Klinikum der Universitaet Muenchen AöR· Forrás
Fut, nem toboroz
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
NCT07220642· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
Antiplatelet therapy added to standard thromboprophylaxis to prevent thrombosis in pancreatic cancer patients - a randomized clinical trial (The PANART trial)
2023-509022-22-00· 3. fázis· Akershus University Hospital· Forrás
Toboroz
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
2024-512753-24-00· 3. fázis· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Forrás
Toboroz
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
NCT06721013· 1/2. fázis· Eli Lilly and Company· Forrás
Toboroz
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
NCT06963827· 3. fázis· Takeda· Forrás
Toboroz
Comprehensive Evaluation of Two Second-Line Therapeutic Approaches for Immune Thrombocytopenia (ITP) – a Pragmatic Randomized Controlled Trial - Holistic Study
2023-505573-32-00· 3. fázis· Ostfold Hospital Trust· Forrás
Toboroz
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
NCT07001800· 2/3. fázis· Kardigan, Inc.· Forrás
Toboroz
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
NCT06959095· 3. fázis· GlaxoSmithKline· Forrás
Toboroz
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
2023-510294-34-00· 3. fázis· University Of Cologne· Forrás
Toboroz
Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab in First-line Metastatic HER2-positive Gastric or GEJ Cancer
2024-513122-27-00· 3. fázis· Daiichi Sankyo Inc.· Forrás
Fut, nem toboroz
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136· 3. fázis· AstraZeneca· Forrás
Toboroz
The Nordic Chronic Migraine Trial of CGRP monoclonal antibody and onabotulinumtoxin A dual therapy – a randomized-controlled double-blind trial (NorMig)
2024-517981-40-00· 3. fázis· Oslo University Hospital HF· Forrás
Toboroz
Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1 randomization to tafasitamab for low-risk disease: a phase II study – NLG-FL7
2023-508196-36-00· 2. fázis· Karolinska University Hospital· Forrás
Toboroz
Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)
NCT06907342· 2. fázis· St. Olavs Hospital· Forrás
Toboroz
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
NCT06929806· 3. fázis· Pharmacosmos A/S· Forrás
Toboroz
Thrombolysis in Factor Xa-inhibitors Trial
NCT06878066· 3. fázis· Guri Hagberg· Forrás
Toboroz
177Lu-DOTATATE for Recurrent Meningioma
NCT06326190· 2. fázis· European Organisation for Research and Treatment of Cancer - EORTC· Forrás
Toboroz
eHealth Based treatment of AdolescenT obesiTy with Low energy diet and sEmaglutide (eBATTLE Obesity)
2023-506289-29-00· 4. fázis· Vestfold Hospital Trust· Forrás
Toboroz
The Norwegian Immunotherapy in Multiple Myeloma Study
NCT06855121· St. Olavs Hospital· Forrás
Contact: Tobias S Slørdahl, MD PhD
Toboroz
Phase III trial of lomustine/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT promoter methylated glioblastoma (IDHwt) patients +/- tumor treating fields (Optune)
2023-506998-35-00· 3. fázis· Vaestra Goetalandsregionen· Forrás
Toboroz
Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma
NCT06488482· 3. fázis· Uppsala University· Forrás
Toboroz
Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA Trial
NCT06653634· 4. fázis· Oslo University Hospital· Forrás
Showing 50 of 133.